Acute Leukemias IV

Prognostic Factors and Treatment Strategies

T. Büchner, W. Hiddemann, B. Wörmann, G. Schellong, J. Ritter (Herausgeber)

Buch | Softcover

XXXVI, 803 Seiten

2011 | 1. Softcover reprint of the original 1st ed. 1994
Springer Berlin (Verlag)
978-3-642-78352-4 (ISBN)

Artikel merken

The rates of acute leukemia cure have gradually improved over the last decade. Clinical study results reflect the impact of chemotherapy intensity and duration, the role of prolonged maintenance, intensified consolidation or very early intensification. Further progress has also been achieved in bone marrow trans plantation, and recent prospective studies and meta-analyses have contributed comparisons of the high antileukemic efficacy of bone marrow transplantation to that of improved chemotherapy. This allows a more successful combining of the two forms of treatment. New prognostic factors have emerged from both cytogenetic and molecular genetic research. Thus, the Philadelphia chromosome translocation and the bcr/abl gene rearrangement have proven to be the dominating risk factor in acute lymphoblastic leukemia. Since the frequency increases with age, differences in prognosis between children and adults can be explained. Evaluation of molecular and immunologic leukemia cell markers has provided a better understanding of residual leukemia in clinical remission, as a prognostic factor and in monitoring the effectiveness of the antileukemic strategy. Recent work on leukemic cell biology has resulted in novel therapeutic approaches such as terminal differentiation by all-trans-retinoic acid, modulation of chemotherapy by hematopoietic growth factors such as GM-CSF and enhancement of immunologic control by cytokines such as interleukin 2. New antimicrobial drugs and the application of mostly empiric anti-infectious strategies have helped reducing the therapeutic risk. Thus, a number of recent achievements have provided us with new options in the management of patients with acute leukemias.

After Acute Leukemias - Pharmakokinetics and Management of Relapsed and Refractory Disease - this volume again turns to clinical trials, first line treatment and primary characterization of acute leukemias. It is a result of the world-wide activities in clinical and laboratory research in this area and represents the state of the art in characterization and treatment of acute leukemias.

The Treatment of Acute Leukemia: Observations by a Marrow Transplanter.- Leukemia Cell Biology.- Novel Therapeutic Approaches.- Etoposide: Update of Clinical Experiences.- Hematopoietic Growth Factors: New Aspects for Leukemia Treatment.- Mitoxantrone: Impact on the Treatment of Leukemias and Lymphomas.- Pharmacokinetics.- ALL in Children.- ALL in Adults.- AML in Children.- AML in Adults.- MDS/Secondary AML.- Bone Marrow Transplantation.- Prevention and Treatment of Infections.- Infection.

Erscheint lt. Verlag	5.12.2011
Reihe/Serie	Haematology and Blood Transfusion Hämatologie und Bluttransfusion
Zusatzinfo	XXXVI, 803 p.
Verlagsort	Berlin
Sprache	englisch
Maße	155 x 235 mm
Gewicht	1251 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hämatologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie
Schlagworte	Acute Lymphoblastic Leukemia • acute myeloid leukemia • biomodulators • Bone marrow • bone morrow transplantation • Cancer • Cell • Chemotherapy • classification • clinical trial • cytogenetics • growth • immunotherapy • Interferon • leukemia • Lymphoma • monitoring residual disease • Oncology • Steroids • Transplantation
ISBN-10	3-642-78352-X / 364278352X
ISBN-13	978-3-642-78352-4 / 9783642783524
Zustand	Neuware